ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2018 American Transplant Congress

    Impact of Direct Acting Antiviral Agents (DAAs) for Hepatitis C Virus (HCV)-Induced Liver Diseases on Registration and Outcome on Waiting List (WL) for Liver Transplant (LT)

    C. Antoine,1 C. Jasseron,1 F. Conti,2 S. Dharancy,3 C. Duvoux,4 A. Coilly.5

    1Medical and Scientific Department, Agence de la Biomedecine, Agence de la Biomedecine, La Plaine Saint Denis, Saint Denis, France; 2Department of Hepatology, University Hospital La Pitie, Paris, France; 3Department of Hepatology, University Hospital Huriez, Lille, Nord Pas de Calais, France; 4Department of Hepatology, University Hospital Henri Mondor, Créteil, Val de Marne, France; 5Department of Hepatology, University Hospital Paul Brousse, Villejuif, Val de Marne, France.

    2d-generation DAAs have dramatically improved the management of patients with HCV, including patients with advanced diseases. In France, since 2013, DAA have been largely used,…
  • 2018 American Transplant Congress

    Impact of Direct Antiviral Therapy for Hepatitis C on Acute Rejection and DSA Formation in Kidney Transplant Recipients

    Z. Zaky, S. Armanyous, L. Herlitz, E. Poggio, J. Augustine.

    Cleveland Clinic, Cleveland, OH.

    Background: Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With recent advent of direct antiviral agents (DAA), there has…
  • 2018 American Transplant Congress

    Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant

    A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.

    Michigan Medicine, Ann Arbor, MI.

    Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
  • 2018 American Transplant Congress

    Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis

    X. Wang,1 P. Tan,1 T. Xiang,2 Y. Qiu,1 T. Song,1 T. Lin.1

    1Department of Urology/Institute of Urology/Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; 2West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.

    Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…
  • 2018 American Transplant Congress

    Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation

    D. Axelrod,1 M. Schnitzler,2 B. Kasiske,3 G. Hess,4 R. Bloom,5 F. Gordon,1 H. Randall,2 K. Lentine.2

    1Lahey Clinic, Burlington; 2Saint Louis U, St. Louis; 3SRTR, Minneapolis; 4Symphony Health, Conshohocken; 5U Penn, Philadelphia.

    Effective treatment for hepatitis C virus (HCV) infection has revolutionized post liver transplant (LTx) care. Administration of direct-acting antiviral agents (DAAs) after HCV+ LTx results…
  • 2018 American Transplant Congress

    Elbasvir-Grazoprevir (Zepatier) is Effective and Safe for the Treatment of Chronic Hepatitis C (HCV) Genotype 1 Virus in the Post Kidney Transplant Patient

    P. Brown, D. Venkat.

    Henry Ford Hospital, Detroit.

    Objective: Limited real world data exists regarding the use of direct acting antivirals (DAA) for HCV viremia in renal transplant patients, particularly those with marked…
  • 2017 American Transplant Congress

    Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.

    S. Jonchhe, J. Husson, J. Casale, R. Adekunle, P. Mathur, J. Gripshover, B. Ravichandran.

    University of Maryland Medical Center, Baltimore, MD

    BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…
  • 2017 American Transplant Congress

    Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.

    C. Skillin, M. Mba, B. Madani, C. Frenette.

    Organ Transplant, Scripps Clinic, La Jolla, CA

    Introduction: Hepatitis C remains an important source of morbidity and mortality post liver transplant. Little is known about the long term effects of direct acting…
  • 2017 American Transplant Congress

    Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis.

    B. Kiberd,1 K. Doucette,2 K. Tennankore.1

    1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada

    Given that Hepatitis C (HCV) can be cured, organs from HCV+ deceased donors might be used in HCV- recipients if treatment at the time of…
  • 2017 American Transplant Congress

    HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.

    J. Emamaullee, M. Bral, G. Meeberg, A. Montano-Loza, V. Bain, D. Bigam, N. Kneteman, A. Shapiro.

    University of Alberta, Edmonton, AB, Canada

    Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences